Puma Biotechnology, Inc. (PBYI) stock
PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.22+0.08 (+1.12%)
Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –
Puma Biotechnology gross margin
Gross margin is gross profit as a percentage of revenue.
Puma Biotechnology's gross margin for the twelve months ending Jun 30, 2026 was 74.8%. For fiscal 2025 it was 74.5%, against 72.1% the year before. The highest annual figure on record is 86.5% in fiscal 2019.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 74.5% | +2.5 |
| FY2024 | Dec 31, 2024 | 72.1% | −1.3 |
| FY2023 | Dec 31, 2023 | 73.4% | −2.4 |
| FY2022 | Dec 31, 2022 | 75.8% | +1.0 |
| FY2021 | Dec 31, 2021 | 74.8% | −7.7 |
| FY2020 | Dec 31, 2020 | 82.5% | −4.0 |
| FY2019 | Dec 31, 2019 | 86.5% | +0.3 |
| FY2018 | Dec 31, 2018 | 86.2% | +6.3 |
| FY2017 | Dec 31, 2017 | 79.9% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 77.9% | +1.4 |
| Q1 FY2026 | Mar 31, 2026 | 76.7% | −0.3 |
| Q4 FY2025 | Dec 31, 2025 | 69.3% | −7.1 |
| Q3 FY2025 | Sep 30, 2025 | 77.7% | +13.8 |
| Q2 FY2025 | Jun 30, 2025 | 76.5% | −0.8 |
| Q1 FY2025 | Mar 31, 2025 | 77.1% | +1.6 |
| Q4 FY2024 | Dec 31, 2024 | 76.4% | +10.1 |
| Q3 FY2024 | Sep 30, 2024 | 63.9% | −12.5 |
| Q2 FY2024 | Jun 30, 2024 | 77.4% | −0.9 |
| Q1 FY2024 | Mar 31, 2024 | 75.5% | +0.5 |
| Q4 FY2023 | Dec 31, 2023 | 66.3% | −8.1 |
| Q3 FY2023 | Sep 30, 2023 | 76.3% | −1.8 |
| Q2 FY2023 | Jun 30, 2023 | 78.3% | +3.3 |
| Q1 FY2023 | Mar 31, 2023 | 75.0% | −1.3 |
| Q4 FY2022 | Dec 31, 2022 | 74.4% | −4.1 |
| Q3 FY2022 | Sep 30, 2022 | 78.1% | +0.3 |
| Q2 FY2022 | Jun 30, 2022 | 74.9% | −2.6 |
| Q1 FY2022 | Mar 31, 2022 | 76.3% | +6.4 |
| Q4 FY2021 | Dec 31, 2021 | 78.5% | −0.7 |
| Q3 FY2021 | Sep 30, 2021 | 77.8% | −2.6 |
| Q2 FY2021 | Jun 30, 2021 | 77.6% | −5.1 |
| Q1 FY2021 | Mar 31, 2021 | 69.9% | −22.0 |
| Q4 FY2020 | Dec 31, 2020 | 79.2% | −6.2 |
| Q3 FY2020 | Sep 30, 2020 | 80.4% | −5.1 |
| Q2 FY2019 | Jun 30, 2019 | 82.7% | +0.1 |
| Q1 FY2019 | Mar 31, 2019 | 91.9% | +1.5 |
| Q4 FY2018 | Dec 31, 2018 | 85.4% | +4.2 |
| Q3 FY2018 | Sep 30, 2018 | 85.6% | +10.7 |
| Q2 FY2018 | Jun 30, 2018 | 82.6% | – |
| Q1 FY2018 | Mar 31, 2018 | 90.4% | – |
| Q4 FY2017 | Dec 31, 2017 | 81.3% | – |
| Q3 FY2017 | Sep 30, 2017 | 74.9% | – |
See a number that looks wrong?